1 gen 2004 anni - FDA approves first "anti-angiogenic" drug, bevacizumab
Descrizione:
Bavacizumab is the first of a new generation of targeted drugs that attacked cancer by blocking blood flow to the tumors.
Aggiunto al nastro di tempo:
Cancer Dates
Data:
